Custo-efetividade de fondaparinux em pacientes com Síndrome Coronariana Aguda sem supradesnivelamento do ST

Pepe, C.; Machado, Márcio; Olimpio, Alexandre; Ramos, Rui Fernando

doi:10.1590/s0066-782x2012005000060

Cited by 7 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lastly, due to bleeding reduction and the consequent smaller rate of mortality and events stemming from fondaparinux use, several studies have shown better cost-benefit of its use in relation to enoxaparin. 16 - 19 An OASIS-5 study subanalysis showed, after 180 days, an average cost reduction of up to 547 dollars per patient in the group that used fondaparinux, highlighting the medication's superiority even further. 16 …”

Section: Discussionmentioning

confidence: 99%

Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data

Soeiro¹,

Silva²,

Roque³

et al. 2016

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

Background:Recent studies have shown fondaparinux's superiority over enoxaparin in patients with non-ST elevation acute coronary syndrome (ACS), especially in relation to bleeding reduction. The description of this finding in a Brazilian registry has not yet been documented.Objective:To compare fondaparinux versus enoxaparin in in-hospital prognosis of non-ST elevation ACS.Methods:Multicenter retrospective observational study. A total of 2,282 patients were included (335 in the fondaparinux group, and 1,947 in the enoxaparin group) between May 2010 and May 2015. Demographic, medication intake and chosen coronary treatment data were obtained. Primary outcome was mortality from all causes. Secondary outcome was combined events (cardiogenic shock, reinfarction, death, stroke and bleeding). Comparison between the groups were done through Chi-Square test and T test. Multivariate analysis was done through logistic regression, with significance values defined as p < 0.05.Results:With regards to treatment, we observed the performance of a percutaneous coronary intervention in 40.2% in the fondaparinux group, and in 35.1% in the enoxaparin group (p = 0.13). In the multivariate analysis, we observed significant differences between fondaparinux and enoxaparin groups in relation to combined events (13.8% vs. 22%. OR = 2.93, p = 0.007) and bleeding (2.3% vs. 5.2%, OR = 4.55, p = 0.037), respectively.Conclusion:Similarly to recently published data in international literature, fondaparinux proved superior to enoxaparin for the Brazilian population, with significant reduction of combined events and bleeding.

show abstract

Section: Discussionmentioning

confidence: 99%

Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data

Soeiro¹,

Silva²,

Roque³

et al. 2016

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

show abstract

Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome

2014

View full text Add to dashboard Cite

Evidence from the present systematic review suggests that the majority of the available treatments represent either cost-saving or cost-effective options for NSTE-ACS patients. Moreover, the cost effectiveness of the available treatments was found to be dependent on various factors, particularly the risk profile of patients and the cost of treatment, and hence there is a need to take these into consideration when making decisions and choices.

show abstract

Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST Elevation Acute Coronary Syndrome in Thailand

Permsuwan

Chaiyakunapruk

Nathisuwan

et al. 2015

Heart, Lung and Circulation

View full text Add to dashboard Cite

Custo-efetividade de fondaparinux em pacientes com Síndrome Coronariana Aguda sem supradesnivelamento do ST

Cited by 7 publications

References 19 publications

Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data

Fondaparinux versus Enoxaparin - Which is the Best Anticoagulant for Acute Coronary Syndrome? - Brazilian Registry Data

Cost Effectiveness of Treatments for non-ST-segment elevation Acute Coronary Syndrome

Cost-Effectiveness Analysis of Fondaparinux vs Enoxaparin in Non-ST Elevation Acute Coronary Syndrome in Thailand

Contact Info

Product

Resources

About